Archives for October 29, 2019

Letter to the Editor

Counterpoint: 3 reasons Right to Try is less flexible than expanded access

In a letter to the editor, Richard Klein, director of expanded access programs and policy for the GE2P2 Global Foundation, outlines three reasons why Right to Try is less flexible than expanded access.

GSK develops new chemical-class antibiotic to fight AMR

GSK announces it initiated Phase III trials for gepotidacin, the first in a new class of antibiotics, as an potential treatment for urinary tract infection.

Bryn declares patient preference for nasal spray over EpiPen

Bryn Pharma presents data from a patient study that showed a consistent choice of its nasal spray formulation of epinephrine over Mylan’s EpiPen.

Deloitte launches MyPath platform: ‘A digital partner in care’

ConvergeHealth by Deloitte has launched a new platform for the health care ecosystem that provides clinical trial participants and patients with personalized support and connection to their care teams.

Following $40m Series A, Escient contacts Eurofins to advance drug discovery

Escient Pharmaceuticals has entered the market after closing a $40m Series A financing round – and has contacted Eurofins Discovery for integrated drug discovery services.